Danish pharmaceutical giant Novo Nordisk reported a 3.9% dip in its stock after highlighting ongoing threats from unauthorized, compounded versions of its popular weight loss drugs Wegovy and Ozempic in the United States. Despite record-breaking sales, concerns mount over counterfeit drugs, falling expectations, and looming cost-cutting measures.